Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia - PubMed (original) (raw)
Clinical Trial
. 1999 Oct;156(10):1646-9.
doi: 10.1176/ajp.156.10.1646.
Affiliations
- PMID: 10518181
- DOI: 10.1176/ajp.156.10.1646
Clinical Trial
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia
C M Adler et al. Am J Psychiatry. 1999 Oct.
Abstract
Objective: This study sought to determine whether thought disorder induced in healthy volunteers by the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine resembles the thought disorder found in patients with schizophrenia.
Method: The Scale for the Assessment of Thought, Language, and Communication was used to assess thought disorder in healthy volunteers (N = 10) who received subanesthetic doses of ketamine and in a group of clinically stable inpatients with schizophrenia (N = 15) who did not receive ketamine.
Results: Mean scores on the Scale for the Assessment of Thought, Language, and Communication for patients with schizophrenia and healthy volunteers receiving ketamine did not differ significantly. Moreover, three of the four highest rated test items in both groups were the same.
Conclusions: These data suggest that ketamine-induced thought disorder in healthy volunteers is not dissimilar to the thought disorder in patients with schizophrenia and provide support for the involvement of the NMDA receptor in a cardinal symptom of schizophrenia.
Similar articles
- Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Anand A, et al. Arch Gen Psychiatry. 2000 Mar;57(3):270-6. doi: 10.1001/archpsyc.57.3.270. Arch Gen Psychiatry. 2000. PMID: 10711913 Clinical Trial. - Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Umbricht D, et al. Arch Gen Psychiatry. 2000 Dec;57(12):1139-47. doi: 10.1001/archpsyc.57.12.1139. Arch Gen Psychiatry. 2000. PMID: 11115327 - [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L. Mechri A, et al. Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French. - Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA. Gouzoulis-Mayfrank E, et al. Pharmacopsychiatry. 2005 Nov;38(6):301-11. doi: 10.1055/s-2005-916185. Pharmacopsychiatry. 2005. PMID: 16342002 Clinical Trial. - The NMDA antagonist model for schizophrenia: promise and pitfalls.
Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. Abi-Saab WM, et al. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9. doi: 10.1055/s-2007-979354. Pharmacopsychiatry. 1998. PMID: 9754841 Review.
Cited by
- Automated analysis of free speech predicts psychosis onset in high-risk youths.
Bedi G, Carrillo F, Cecchi GA, Slezak DF, Sigman M, Mota NB, Ribeiro S, Javitt DC, Copelli M, Corcoran CM. Bedi G, et al. NPJ Schizophr. 2015 Aug 26;1:15030. doi: 10.1038/npjschz.2015.30. eCollection 2015. NPJ Schizophr. 2015. PMID: 27336038 Free PMC article. - Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes.
Zuccoli GS, Reis-de-Oliveira G, Garbes B, Falkai P, Schmitt A, Nakaya HI, Martins-de-Souza D. Zuccoli GS, et al. Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1579-1586. doi: 10.1007/s00406-021-01248-w. Epub 2021 Mar 10. Eur Arch Psychiatry Clin Neurosci. 2021. PMID: 33751207 - Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism.
Gottschalk MG, Wesseling H, Guest PC, Bahn S. Gottschalk MG, et al. Int J Neuropsychopharmacol. 2014 Oct 31;18(2):pyu019. doi: 10.1093/ijnp/pyu019. Int J Neuropsychopharmacol. 2014. PMID: 25609598 Free PMC article. - Early auditory processing dysfunction in schizophrenia: Mechanisms and implications.
Dondé C, Kantrowitz JT, Medalia A, Saperstein AM, Balla A, Sehatpour P, Martinez A, O'Connell MN, Javitt DC. Dondé C, et al. Neurosci Biobehav Rev. 2023 May;148:105098. doi: 10.1016/j.neubiorev.2023.105098. Epub 2023 Feb 14. Neurosci Biobehav Rev. 2023. PMID: 36796472 Free PMC article. Review. - Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice.
Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, Dong H. Csernansky JG, et al. Neuropsychopharmacology. 2005 Dec;30(12):2135-43. doi: 10.1038/sj.npp.1300761. Neuropsychopharmacology. 2005. PMID: 15956997 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical